Stockholm, Sweden, November 6, 2018 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 15, 2018 the members of the Nomination Committee for the 2019 Annual General Meeting shall be appointed through a procedure where the three largest shareholders in terms of voting power according to Euroclear’s transcription of the share register as of September 30, 2018 are contacted by the Chairman of the Board and asked to appoint one representative each to the Nomination Committee. If any of the three largest shareholders does not wish to appoint a member of the Nomination Committee, another shareholder shall be asked, and so forth until the Nomination Committee consists of three members.
September 30, 2018, the three largest shareholders were Demban AB, Ackelsta AB and The Fourth Swedish National Fund (AP4). The latter, however, has chosen to give up its seat in the Nomination Committee for the benefit of The Third Swedish National Pension Fund (AP3), which is the company’s fourth largest shareholder as of September 30, 2018.
The Nomination Committee, whose tasks include providing proposals to the Annual General Meeting 2019 regarding Chairman of the Meeting, Board members, Chairman of the Board, Deputy Chairman of the Board, fees to the board members, any remuneration for committee work, proposal for and fees to the company’s auditor as well as principles for composition of the Nomination Committee, comprises:
- Margareta Öhrvall, appointed by Demban AB
- Claes Andersson, appointed by Ackelsta AB
- Gunnar Blix, appointed by The Third Swedish National Pension Fund
The Nomination Committee elects its Chairman.
Together the members of the Nomination Committee represent approx. 63.15 percent of the shares and approx. 85.09 percent of the votes in the company (as of September 30, 2018).
Shareholders wishing to submit a proposal to BioArctic’s Nomination Committee can do so by e-mail to: ir@bioarctic.se (label e-mails with ”Nomination Committee”) or by letter addressed to:
BioArctic AB, Att: Nomination Committee, Warfvinges väg 35, SE-112 51 Stockholm, Sweden, not later than March 29, 2019.
The Nomination Committee’s proposals will be presented in the Notice to the Annual General Meeting 2019 and on BioArctic’s website, www.bioarctic.com.
The Annual General Meeting 2019 in BioArctic will be held on Tuesday, May 9, 2019 at 4:00 p.m. (CET) in Stockholm. A request to have a matter dealt with at the meeting must be received by March 8, 2019 to be included in the notice.
Future dates for reporting from BioArctic AB:
| Full Year Report 2018 | February 20, 2019, at 8:00 a.m. CET |
| Publication of the Annual Report 2018 | Week commencing April 15, 2019 |
| Interim Report January – March 2019 | May 9, 2019, at 8:00 a.m. CET |
| Annual General Meeting 2019 | May 9, 2019, at 4:00 p.m. CET |
| Interim Report January – June 2019 | Jul 11, 2019, at 8:00 a.m. CET |
| Interim Report January – September 2019 | Oct 24, 2019, at 8:00 a.m. CET |
For more information, please contact:
Jan Mattsson, CFO
Telephone: + 46 (0)70 352 27 72
E-mail: jan.mattsson@bioarctic.se
Christina Astrén, Head IR & Communications
Telephone: + 46 (0)70 835 43 36
E-mail: christina.astren@bioarctic.se
This information was submitted for publication at 08:00 p.m. (CET), on November 6, 2018.
About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap
(ticker: BIOA B). www.bioarctic.com